
Bavarian Nordic has secured million-dollar incomes for the next few years, as the US Biomedical Advanced Research and Development Authority (BARDA) has utilized its contracted option on Bavarian’s freeze-dried smallpox vaccine, Jynneos.
Søren Løntoft Hansen, who is a senior analyst at Danish bank Sydbank, says this sends a positive signal.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app